Episode
Building Agent Studio: How Medable Is Using Agentic AI to Accelerate Clinical Trials
- Podcast
- Just Now Possible
- Published
- Mar 19, 2026
- Duration seconds
- 3973
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/just-now-possible-7481489/episodes/building-agent-studio-how-medable-is-using-agentic-ai-to-accelerate-clinical-trials/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/just-now-possible-7481489/building-agent-studio-how-medable-is-using-agentic-ai-to-accelerate-clinical-trials.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
What if AI could help reduce the 10-plus years it takes to get a new drug to market? That's the driving ambition behind Medable's agentic platform—and the bet that led them to build Agent Studio. In this episode of Just Now Possible, Teresa Torres talks with four members of the Medable team: Luke Bates (Product Leader, Agent Studio), Jen Brown (Product Manager), Matt Schoolfield (Product Designer), and Fiachra Matthews (Principal Architect). Together they share how Medable—a clinical trial platform used by global pharmaceutical companies—built Agent Studio, a no-code/low-code platform for configuring and deploying agents across the clinical trial lifecycle. You'll hear about the two agents they've built on top of it: an ETMF agent that automates document classification across 80,000-plus documents per year, and a CRA agent that monitors patient safety and data quality across 13 different clinical systems. The conversation goes deep on the architecture behind it all—how they handle RAG and context management at scale, why they built custom MCPs with an authentication layer, how they designed evals for a regulated GXP environment, and what human-in-the-loop really looks like when clinical decisions are on the line. It's a rare look inside an enterprise AI platform built for one of the most regulated industries in the world—and a team that's still figuring it out in real time.